Model List of Essential Medicines

Aztreonam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection	Other specified bacterial diseases

Cefiderocol

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Ceftaroline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection	Other specified bacterial diseases

Ceftazidime + avibactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Ceftolozane + tazobactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 1 g + 0.5 g powder for injection	Carbapenem-resistant Pseudomonas aeruginosa

Colistin (injection)

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) ◦ Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)	Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Daptomycin

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection	Other specified bacterial diseases

Eravacycline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 50 mg lyophilized powder for injection	Other carbapenem resistant Enterobacterales

Fifth generation cephalosporins

Section	Indications
Reserve group antibiotics ◦ .	Other specified bacterial diseases

Fosfomycin (injection)

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection	Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales

Imipenem + cilastatin + relebactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection ◦ Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection	Other specified other antibiotic resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales

Linezolid

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 2 mg per mL in 300 mL bag ◦ Oral > Liquid: 100 mg per 5 mL powder for oral liquid ◦ Oral > Solid: 400 mg tablet; 600 mg tablet ◦ Oral > Solid > dispersible tablet: 150 mg ◦ Oral > Solid > tablet: 600 mg	Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus

Meropenem + vaborbactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Acinetobacter baumannii Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Omadacycline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 100 mg lyophilized powder for injection ◦ Oral > Solid: 300 mg	Methicillin resistant Staphylococcus aureus

Oxazolindinones

Section	Indications
Reserve group antibiotics ◦ .	Other specified bacterial diseases

Plazomicin

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 500 mg per 10 mL	Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Escherichia coli Carbapenem resistant Klebsiella pneumoniae

Polymyxin B (injection)

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)	Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Acinetobacter baumannii Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Polymyxins

Section	Indications
Reserve group antibiotics ◦ .	Other specified bacterial diseases

Tedizolid

Section	Indications
Reserve group antibiotics	Therapeutic equivalent to linezolid for Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Enterococcus

Tigecycline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 50 mg in vial powder for injection	Other specified bacterial diseases